Anthony Bishop

Prof. Anthony Bishop


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2015 in Biochemistry
Verified
Journal Article
Open access
CCCynthia M. Chio
Cynthia M. Chio
CLChristopher S. Lim
Christopher S. Lim
ABAnthony Bishop
Anthony Bishop
Protein tyrosine phosphatases (PTPs) have been the subject of considerable pharmaceutical-design efforts because of the ubiquitous connections between misregulation of PTP activity and human disease. PTP-inhibitor discovery has been hampered, however, by the difficulty in identifying cell-permeable compounds that can selectively target PTP active sites, and no PTP inhibitors have progressed to the clinic. The identification of allosteric sites on target PTPs therefore represents a potentially attractive solution to the druggability problem of PTPs. Here we report that the oncogenic PTP Shp2 contains an allosteric-inhibition site that renders the enzyme sensitive to potent and selective inhibition by cell-permeable biarsenical compounds. Because Shp2 contains no canonical tetracysteine biarsenical-binding motif, the enzyme’s inhibitor-binding site is not readily predictable from its primary or three-dimensional structure. Intriguingly, however, Shp2’s PTP domain does contain a cysteine residue (C333) at a position that is removed from the active site and is occupied by proline in other classical PTPs. We show that Shp2’s unusual cysteine residue constitutes part of a Shp2-specific allosteric-inhibition site, and that Shp2’s sensitivity to biarsenicals is dependent on the presence of the naturally occurring C333. The determinative role of this residue in conferring inhibitor sensitivity is surprising because C333’s side chain is inaccessible to solvent in Shp2 crystal structures. The discovery of this cryptic Shp2 allosteric site may provide a means for targeting Shp2 activity with high specificity and suggests that buried-yet-targetable allosteric sites could be similarly uncovered in other protein families.

20 November 2018 in ACS Omega
Verified
Journal Article
Open access
BMBrennan Marsh-Armstrong
Brennan Marsh-Armstrong
JFJesse M. Fajnzylber
Jesse M. Fajnzylber
SKSamuel Korntner
Samuel Korntner
BPBailey A. Plaman
Bailey A. Plaman
ABAnthony Bishop
Anthony Bishop
Difficulties in developing active-site-directed protein tyrosine phosphatase (PTP) inhibitors have led to the perception that PTPs are “undruggable”, highlighting the need for new means to target pharmaceutically important PTPs allosterically. Recently, we characterized an allosteric-inhibition site on the PTP domain of Src-homology-2-domain-containing PTP 2 (SHP2), a key anticancer drug target. The central feature of SHP2’s allosteric site is a nonconserved cysteine residue (C333) that can potentially be labeled with electrophilic compounds for selective SHP2 inhibition. Here, we describe the first directed discovery effort for C333-targeted allosteric SHP2 inhibitors. By screening a previously reported library of reversible, covalent inhibitors, we identified a lead compound, which was modified to yield an irreversible inhibitor (12), that inhibits SHP2 allosterically and selectively through interaction with C333. These findings provide a novel paradigm for allosteric-inhibitor discovery on SHP2, one that may help to circumvent the challenges inherent in targeting SHP2’s active site.

9 March 2007 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
XZXin-Yu Zhang
Xin-Yu Zhang
ABAnthony Bishop
Anthony Bishop

20 September 2008 in Journal of Chemical Biology
Verified
Journal Article
Closed access
PDF file
ABAnthony Bishop
Anthony Bishop
VCVincent Chen
Vincent Chen

1 June 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
CCCynthia M. Chio
Cynthia M. Chio
XYXiaoling Yu
Xiaoling Yu
ABAnthony Bishop
Anthony Bishop

31 August 2023 in Analytical Biochemistry
Verified
Journal Article
Closed access
ASAnna Serbina
Anna Serbina
ABAnthony Bishop
Anthony Bishop